Parameswaran Hari
Hematology & Oncology · Milwaukee, WINPI 1083665814
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,145,347 of the $1,285,898 with a category attached, or 89.1%. Pfizer accounts for 61.9% of it on its own, with 23 other manufacturers making up the rest. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $4559.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$796K
- GSK$210K
- Bristol Myers Squibb$100K
- Karyopharm Therapeutics Inc.$37K
- Johnson & Johnson$27K
- Sanofi-aventis U.S. LLC$20K
- plus $96K from 18 others
Across 275 payments — averaging $18,109 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.3M
- Janssen Research & Development, LLC$915K
- Sanofi$802K
- Amgen$655K
- Takeda Pharmaceuticals U.S.A., Inc.$537K
- AbbVie$281K
- plus $467K from 10 others
What the payments were for
- Consulting fees$1,145,34789%
- Speaking & faculty fees$117,3709%
- Travel & lodging$17,9151%
- Food & beverage$5,2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 46 | $796,238 |
| GSK | 26 | $210,063 |
| Bristol Myers Squibb | 76 | $99,702 |
| Karyopharm Therapeutics Inc. | 14 | $36,737 |
| Johnson & Johnson | 26 | $26,753 |
| Sanofi-aventis U.S. LLC | 4 | $19,925 |
| Sanofi | 15 | $19,592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $19,289 |
| Incyte Corporation | 13 | $16,281 |
| Amgen | 19 | $11,280 |
| Adaptive Biotechnologies Corporation | 13 | $10,901 |
| Kadmon Pharmaceuticals LLC | 4 | $6,118 |
| Janssen Global Services, LLC | 3 | $4,535 |
| Omeros Corporation | 1 | $2,250 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $2,100 |
| Genentech, Inc. | 3 | $1,282 |
| Janssen Research & Development, LLC | 1 | $1,200 |
| Celularity Inc. | 1 | $1,000 |
| E.r. Squibb & Sons, L.L.C. | 2 | $177 |
| Kadmon Corporation LLC | 1 | $144 |
| Genmab U.S., Inc. | 1 | $111 |
| Jazz Pharmaceuticals Inc. | 1 | $106 |
| Rigel Pharmaceuticals, Inc. | 1 | $60 |
| TG Therapeutics, Inc. | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,285,898 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
- Renju Vechurettu RajMilwaukee$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.